Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. - Spigel, David R.; Burris, Howard A.; Greco, F. Anthony; Shih, Kent C.; Gian, Victor G.; Lipman, Andrew J.; Daniel, Davey B.; Waterhouse, David M.; Finney, Lindsey; Heymach, John V.; Hainsworth, John D.; Burris, Howard A 3rd (Cancer (0008543X), 2018)